Guerreiro HAM, Villaescusa BR, Leyva RA, Merlín LJC, Arce HAA, Lam DRM

Language: Spanish
References: 21
Page: 388-393
PDF size: 52.01 Kb.

ABSTRACT

Introduction: Several studies have demonstrated the presence of anti-C1q antibodies in patients with systemic lupus erythematosus, although their participation in the pathogenesis of the disease is not fully clarified. The C1q plays a role in removing immune complexes and apoptotic cell debris, known source auntoantigens, and maintenance of the vascular endothelium. There is a wide variety of autoantibodies as antinuclear antibodies, anti double and single stranded DNA alongside the anti-C1q antibodies are used as diagnostic markers in patients with this disease.
Objective: To determine the prevalence of antibodies to C1q in the active phase of the disease.
Methods: The levels of anti-C1q antibodies were determined by an enzyme-linked immunosorbent assay (Orgentec) in the serum of 64 patients: 20 with systemic lupus erythematosus in active phase according to the index of activity of systemic lupus erythematosus, 44 with other rheumatic autoimmune diseases, and 30 healthy donors. The study was conducted in the period from 2013 to 2015.
Results: Anti C1q antibodies were detected in the sera of 8 of the 20 patients with lupus in active phase (40%), the presence of anti C1q antibody was demonstrated in nine of those with other rheumatologic diseases autoimmune (20.5%) and 4 of the healthy individuals (13.3%).
Conclusions: These results suggest the possible involvement of anti C1q antibodies in the existing damage in the active phase of the disease.

REFERENCES

1. Hasan SL, Mohdashari NS, Mohd DK, Chehusin CM. High occurrence of in vitro apoptosis of lymphocytes induced by serum from systemic lupus erythematosus patients is associated with increased serum levels of anti-C1q autoantibodies. Int J Rheum Dis. 2013;16(4):430-36.

2. Roumenina LT, Sene D, Radanova M, Blouin J, Halbwachs-Mercarelly L, Dragon- Durey MA. Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance. J Immunol. 2011;187(8):4369-73.

3. Jozsef P, Laszlo C. The endotelial deprotection hipothesis for lupus pathogenesis, the dual role of C1q as a mediator of clearance and regulator of endothelial permeability. Research. 2015;4:24.

4. Radanova M, Vasilev V, Dimitrov T. Associaton of C1q gene cluster polymorphism with lupus nefritis in bulgarian patients. Lupus. 2015; 24:3280-9.

5. Sato N, Ohsawa I, Nagamachi S, Ishii M, Kusaba G, Inoshita M, et al. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus. 2011;20:1378-86.

6. Kelley JM, Edberg JC, Kimberley RP. Pathways strategies for susceptibility genes in LES. Autoimmune Rev. 2010;9:473-9.

7. Bruner BF, Guthridge JM, Lu R, Vidal G, Kelly JA. Comparison of autoantibody specificities between traditional and bead- based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members. Artritis Rheum. 2012;64:3677-86.

8. Pisetsky DS. Antinuclear antibodies in rheumatic disease: a proposal for a funtionbased classification. Scand J Immunol. 2012;76:223-28.

9. Orbai AM, Truedsson L, Sturfelt G, Nived O. Anti-C1q antibodies in systemic lupus erythematosus. Lupus. 2015;24:42-9.

10. Katsumata Y, Miyake K, Kawaquchi Y, Okamoto Y. Anti C1q antibodies are associated with systemic lupus erithematosus global activity but not specifically with nephritis: A controlled study of 126 consecutive patients. Arthritis Rheum. 2011; 63(8):2436-44.

11. Eggleton P, Ukoumunne OC, Cotrell L, Khan A. Autoantibodies against C1q as a diagnostic measure of a lupus nephritis systematic review and meta-analysis. J Clin Cell. 2014;22(2):210.

12. Wisniesky JJ, Jones SM. Comparision of autoantibodies to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis síndrome and systemic lupus erthematosus. J Immunol. 1992;148:1396-1403.

13. Potlukova E, Kralikova P. Complement component C1q and anti C1q antibodies in theory and in clinical practice. Scand J Immunol. 2008;67:423-30.

14. Bassyouni H, Gamal S, Talaat RM, Siam I. Autoantibodies against complement C1q in patients with Behçet disease: Association with vascular involvement. Mod Rheumatol. 2014;24(2):316-2.

15. Takei T, Itabashi M, Moriyama T, Shimizu A. Positive C1q staining associated with poor renal outcome in membrano proliferative glomerulonephritis. Clin Exper Nephrol. 2013;17(1):92-8.

16. Prohaszka Z, Daha MR, Susal C, Daniel V, Szlavick J, Banhegyi D. C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-KDa heat- shock proteins. Clin Immunol. 1999;90:247-55.

17. Fadda SH, Bassyounil H, Foad NA, Wali IE. Anti C1q in chronic hepatitis C virus genotype IV infection rheumatologic manifestatioins. Immunol Invest. 2014;16:1-11.

18. Siegert CE, Daha MR, Swaak AJ, Van der voort. The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic lupus erythematosus. Immunol Immunopathol. 1993;67:204-9.

19. Yin Y, Wu X, Shan G, Zhang X. Diagnostic value of serum anti C1q antibodies in patients with lupus nephritis: A meta- analysis. Lupus. 2012; 21:1088-97.

20. Orbai A.M, Truedsson L, Sturfelt G, Nived O. Anti- C1q antibodies in systemic lupus erythematosus. Lupus. 2015;24:42-9.

21. Mahler M, Van Scharenburg R, Trouw L. Anti C1q autoantibodies, novel tests and clinical consequences. Frontiers Inmunol. 2013;117: 1-5.